Sotiburafusp Alfa (Research-Grade) is a research-grade biosimilar monoclonal antibody targeting CD1. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays, in vivo research and Western blot. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor.
Product Name:
Sotiburafusp Alfa (Research-Grade)
SKU:
GXBS02102
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
B7 homolog 1
Isotype:
IgG1-kappa, fused with humanized vascular endothelial growth factor receptor 1/VEGFR-1 extracellular domain fragment
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo, WB
Synonyms:
2637466-37-4
Recommended Dilutions:
WB: 1:500-1:2000
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Human hyaluronidase isozyme-5/HYAL5 fragment engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1/HYAL1.
